الفهرس 
INTRODUCATION AND AIM OF THE WORKOnly 14 pages are availabe for public view
 |  | from | 203 |  |  |
| | | from | 203 | | |
Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide, with the incidence on the rise both in the United States and abroad (Siegel et al., 2012). Globally, there are approximately 750,000 new cases of liver cancer reported per year.
Population-based studies show that the incidence rate continues to approximate the death rate, indicating that most of the patients who develop HCC die from it. Five-year survival rates in the United States have improved modestly to approximately 26%, an improvement that is believed to be associated with improved surveillance in identifiable high-risk patients (i.e., those with hepatitis B and C viruses) and surgical intervention (resection or transplant) for patients with early- stage disease (Jemal.et al., 2011). Egypt has the rising rates of hepatocellular carcinoma (HCC).The currently increasing incidence of HCC in Egyptians may be due to shift of the relative importance of HCV as primary risk factors (El-Zayadi et al., 2005) . HCC is the second most frequent cause of cancer incidence and mortality among men at Egypt (Freedman et al., 2006). Liver transplantation (LT) is the optimal therapy for patients with HCC because it removes not only the tumor but also the underlying cirrhotic liver that is at risk for the development of de novo HCC (Poon et al., 2001). However, the shortage of donor organs represents the major problem in applying primary transplantation to all patients.